CEL-SCI Corporation

CEL-SCI Corporation is a biotechnology company dedicated to the research and development of immunotherapy products aimed at treating cancer, autoimmune, and infectious diseases. The company's mission is to improve disease treatment by leveraging the body's natural immune system. Headquartered in Vienna, Virginia, CEL-SCI focuses on developing novel immune-based therapies with the potential for minimal toxicity.

CEL-SCI's primary investigational therapy is Multikine® (Leukocyte Interleukin, Injection), which has completed a Phase 3 clinical trial for the treatment of head and neck cancer and is currently advancing towards a confirmatory registration study. Multikine has received Orphan Drug designation from the FDA for neoadjuvant therapy in squamous cell carcinoma of the head and neck. Additionally, the company is developing the LEAPS™ (Ligand Epitope Antigen Presentation System) technology, a platform for therapeutic vaccines designed to stimulate the immune system against bacterial, viral, parasitic infections, autoimmune conditions, and certain cancers, including potential treatments for rheumatoid arthritis.

Led by CEO Geert Kersten, who has been with the company since 1987 and in his current role since 1995, CEL-SCI is a clinical-stage biotechnology firm. Recent developments include the closing of a public offering of common stock and a strategic agreement with Saudi Amarox for the commercialization and distribution of Multikine in Saudi Arabia, with an option to expand to other Gulf Cooperation Council countries. The company is also preparing to commence a confirmatory registration study for Multikine in the U.S.